Li M - Search Results

1

Nomogram to predict contralateral breast cancer risk in breast cancer survivors: A SEER-based study.

Tong J, Tan D, Ma J, Hu Y, Li M. Tong J, et al. Among authors: li m. Medicine (Baltimore). 2021 Nov 19;100(46):e27595. doi: 10.1097/MD.0000000000027595. Medicine (Baltimore). 2021. PMID: 34797281 Free PMC article.

2

Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C. Zhang H, et al. Among authors: li m. Oncotarget. 2015 Apr 30;6(12):10658-66. doi: 10.18632/oncotarget.3381. Oncotarget. 2015. PMID: 25826084 Free PMC article.

3

FSIP1 is correlated with estrogen receptor status and poor prognosis.

Li X, Song X, Ma J, Zhao Y, Jiang Q, Zhao Z, Li M. Li X, et al. Among authors: li m. Mol Carcinog. 2020 Jan;59(1):126-135. doi: 10.1002/mc.23134. Epub 2019 Nov 12. Mol Carcinog. 2020. PMID: 31713931

4

Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.

Xu L, Xu F, Kong Q, Yang T, Tan D, Zhang X, Li N, Zhao S, Zhao J, Li M. Xu L, et al. Among authors: li m, li n. Mol Carcinog. 2020 Aug;59(8):967-979. doi: 10.1002/mc.23215. Epub 2020 May 19. Mol Carcinog. 2020. PMID: 32424979

5

Screening potential microRNAs associated with pancreatic cancer: Data mining based on RNA sequencing and microarrays.

Ma J, Sun S, Song C, Li N, Li N, Xu L, Yang T, Lan Y, Li M. Ma J, et al. Among authors: li m, li n. Exp Ther Med. 2020 Sep;20(3):2705-2715. doi: 10.3892/etm.2020.8991. Epub 2020 Jul 13. Exp Ther Med. 2020. PMID: 32765765 Free PMC article.

6

An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.

Sui S, An X, Xu C, Li Z, Hua Y, Huang G, Sui S, Long Q, Sui Y, Xiong Y, Ntim M, Guo W, Chen M, Deng W, Xiao X, Li M. Sui S, et al. Among authors: li z, li m. Theranostics. 2020 Oct 25;10(26):11938-11949. doi: 10.7150/thno.49451. eCollection 2020. Theranostics. 2020. PMID: 33204321 Free PMC article.

7

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer.

Hu Y, Gao J, Wang M, Li M. Hu Y, et al. Among authors: li m. Cancer Manag Res. 2021 Jul 1;13:5223-5237. doi: 10.2147/CMAR.S310649. eCollection 2021. Cancer Manag Res. 2021. PMID: 34234565 Free PMC article. Review.

8

A potential role for metastasis-associated in colon cancer 1 (MACC1) as a pan-cancer prognostic and immunological biomarker.

Hu Y, Wang M, Wang K, Gao J, Tong J, Zhao Z, Li M. Hu Y, et al. Among authors: li m. Math Biosci Eng. 2021 Sep 23;18(6):8331-8353. doi: 10.3934/mbe.2021413. Math Biosci Eng. 2021. PMID: 34814302 Free article.

9

A novel mutant PIK3R1^EY451delinsD breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report.

Wang K, Hu Y, Xu L, Zhao S, Song C, Sun S, Li X, Li M. Wang K, et al. Among authors: li x, li m. Mol Biol Rep. 2022 Jul;49(7):6155-6160. doi: 10.1007/s11033-022-07407-z. Epub 2022 Apr 6. Mol Biol Rep. 2022. PMID: 35384625

10

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations.

Ma J, Li X, Zhang Q, Li N, Sun S, Zhao S, Zhao Z, Li M. Ma J, et al. Among authors: li x, li m, li n. Transl Oncol. 2022 Jul;21:101444. doi: 10.1016/j.tranon.2022.101444. Epub 2022 May 3. Transl Oncol. 2022. PMID: 35523006 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75,198 results

Search Page

Filters